Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization

ConclusionCerebral pseudoprogression followed three distinct patterns and was detectable in 3.2% of all patients during ICI treatment and in 9.75% of the patients with sufficient brain imaging follow up. The fact that all but one of the affected patients developed neurological symptoms, which would be classified as progressive disease according to iRANO criteria, mandates vigilance in the diagnosis and treatment of ICI-induced cerebral lesions.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research